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The antileukemic potential of natural killer (NK) cells has been of rising interest in recent
years. Interactions between inhibitory killer cell immunoglobulin-like receptors (KIR) and
HLA class I ligands seem to be critically involved in the immunosurveillance process. It is
also well established that mismatching of HLA class I-encoded KIR ligands in the setting
of hematopoietic stem cell transplantation leads to allorecognition of leukemic cells by
NK cells, which is in line with the concept of missing-self recognition. Recent data now
suggest that KIR gene polymorphism constitutes another important parameter that needs
to be taken into account for selection of suitable stem cell donors. Moreover, the role of
KIR gene polymorphism for predisposition to leukemia is a current matter of debate. Here,
we would like to review the role of KIR function and genetic polymorphism for recognition
of leukemia and discuss the impact of these ﬁndings for developing novel concepts for NK
cell-based immunotherapy strategies.
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INTRODUCTION
Natural killer (NK) cells represent a subset of innate lymphoid
cells that act as ﬁrst line of defense against viral infections, early
cellular transformation and tumor growth (Lanier, 2005; Spits and
Di Santo, 2011). The “missing-self” concept, put forward by Kärre
and colleagues in the 1980s, formed the basis for understanding
NK-derived allorecognition by describing one simplistic mecha-
nism by which NK cells target tumor cells deﬁcient in MHC-I
expression (Kärre et al., 1986; Lanier, 2005). According to this
hypothesis NK cells expressing a cognate inhibitory receptor for
the respective major histocompatibility complex (MHC) class I
molecule can detect target cells via their reduced or “missing”
expression of “self” MHC class I (Ljunggren and Karre, 1990;
Algarra et al., 1997). In humans this is based on human leuko-
cyte antigen (HLA) class I-speciﬁc receptors, which are mainly
encoded by the killer cell immunoglobulin-like receptor (KIR)
family and the lectin-like receptor family of NKG2 genes. Addi-
tional MHC class I receptors are encoded by the LIR gene family
(Colonna et al., 1997; Cosman et al., 1997). KIRs are the genetically
most polymorphic of these receptors, interacting with the equally
polymorphic HLA class I system. In rodents, in the absence of
KIR genes, a comparable MHC class I-speciﬁc system is in place
encoded by the Ly49 family (Karlhofer et al., 1992; Raulet et al.,
1997; Trowsdale et al., 2001).
Killer cell immunoglobulin-like receptors recognize speciﬁc
motifs of HLA class I molecules, which are the products of highly
polymorphic genes of the MHC located on chromosome 6 (Klein
and Sato, 2000a,b; Vilches and Parham, 2002; Marsh et al., 2010).
HLA-Cplays a key role forKIR-mediated recognition of target cells
and all allelic variants invariably provide ligands for inhibitory
KIR. All HLA-C allotypes carry valine (V) at position 76, while
position 80 displays a dimorphism of either asparagine or lysine.
HLA-C group 1 with asparagine at position 80 provides the ligand
for KIR2DL2 and KIR2DL3, whereas HLA-C group 2 with lysine
at position 80 provides the ligand for KIR2DL1. However, it has
been shown recently thatKIR2DL2 and to a lesser extendKIR2DL3
bind to certain HLA-C2 group alleles as well, while KIR2DL1
exhibits exquisite speciﬁcity forHLA-C2only (Moesta et al., 2008).
KIR3DL1 binds the HLA-B motif Bw4, which is also present
on some HLA-A molecules whereas KIR3DL2 has speciﬁcity for
HLA-A alleles (A3 and A11) but also for CpG oligonucleotides
(Marcenaro et al., 2009). The ligand speciﬁcity of stimulatory KIR
is less well described with the exception of KIR2DS1. Activating
KIR2DS1 and inhibitory KIR2DL1 share ligand speciﬁcity for the
HLA-C2 group, which is consistent with their highly similar extra-
cytoplasmic domain. In case of KIR2DS4, weak but signiﬁcant
interactions with subsets of HLA-C alleles as well as HLA-A*11
could be detected (Graef et al., 2009). The ligands of KIR3DS1
have yet to be identiﬁed but recent studies have suggested that the
HLA-Bw4-T80 allotype HLA-B*2705 is a potential putative ligand
for KIR3DS1 (Martin et al., 2002; Alter et al., 2007, 2009; Korner
and Altfeld, 2012). Speciﬁcity of the stimulatory KIR KIR2DS2,
KIR2DS3, and KIR2DS5 is not known and might comprise also
non-HLA ligands (Kim et al., 1997; Vales-Gomez et al., 1998; Win-
ter et al., 1998; Vilches and Parham, 2002; Carr et al., 2007; Della
Chiesa et al., 2008; VandenBussche et al., 2009).
Killer cell immunoglobulin-like receptors are displayed on
the surface of NK cells in diverse combinations. This clonally-
distributed expression mode leads to the generation of complex
NK cell repertoires, which basically comprise NK cells expressing
all possible combinations of receptors (Valiante et al., 1997; Raulet
et al., 2001; Yawata et al., 2006; Andersson et al., 2010; Schon-
berg et al., 2011a). The clonal expression mode and the cell type
speciﬁcity of KIR genes are epigenetically regulated on the lev-
els of DNA methylation and histone modiﬁcations in addition to
promoter-derived transcriptional regulation (Uhrberg, 2005b).
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NK CELL-MEDIATED TUMOR SURVEILLANCE
Natural killer cell function is determined by the net effect of
signaling through several receptor families including activating,
inhibiting, adhesion, and cytokine receptors. In this way, NK cells
have demonstrated not only the ability of killing virally infected
cells, but also of exerting antitumor cytotoxicity against lym-
phoblastic or myeloid hematologic malignancies and solid tumors
like ovarian, breast, and colon cancer (Pende et al., 2005; Re et al.,
2006; Stein et al., 2006). Notably, it has been shown that cyto-
toxicity of NK cells in the peripheral blood of leukemia patients
is signiﬁcantly reduced (Costello et al., 2002; Fauriat et al., 2007).
Various mechanisms and characteristics could account for this
reduced cytotoxicity: (a) an increased expression of MHC class
I on leukemic blasts, (b) a reduced expression of ligands of var-
ious stimulatory NK cell receptors like NKG2D, NCR, and KIR
on leukemic blasts, and (c) a reduced expression of these activat-
ing receptors on NK cells of patients with leukemia (Nowbakht
et al., 2005; Szczepanski et al., 2010). Most of the investigations so
far concerning the role of NK cells in leukemia dealt with adult
patients suffering from acute myeloid leukemia (AML; Moretta
et al., 2011). Little is known regarding the role of NK cells in
the emergence and prevention of acute lymphoblastic leukemia
(ALL), especially in the pediatric setting. Several studies suggest
a less efﬁcient interaction between NK cells and ALL blasts com-
pared to the interaction between NK cells and AML blasts at the
time of diagnosis (Nasrallah and Miale, 1983; Ruggeri et al., 2008).
In this regard, surface density of HLA class I molecules seems to be
higher onALL compared to AML blasts (Pende et al., 2005). Other
mechanisms of immune escape in ALL might be the absence or
down-regulation of ligands for activating NK cell receptors and
the expression of ligands for inhibitory receptors. Remarkably,
information on the expression of KIR on NK cells of patients suf-
fering from acute leukemia is scarce. Thus, the inﬂuence of an
emerging acute or chronic leukemia on the functional NK cell
repertoire as well as the question of adaptation to self-HLA class I
and the licensing status in ALL patients remain to be analyzed
in detail.
In HLA class I-matched hematopoietic stem cell transplan-
tation (HSCT), NK cells were shown to contribute to leukemia
surveillance based on the speciﬁc make-up of their KIR locus
(Cooley et al., 2009, 2010). Interestingly, stimulatory KIR genes
are emerging as important variables in this process (Venstrom
et al., 2012). Since speciﬁcity of most of the stimulatory KIR genes
is not well deﬁned, the precise mechanism of their contribution
constitutes a challenging but important question.
LICENSING AND ALLOREACTIVITY
Since KIR and HLA class I genes segregate on different chro-
mosomes, a tolerance mechanism has to be in place to prohibit
development of autoreactive NK cells, e.g., NK cells with an
inhibitory KIR for HLA class I ligands not present in the genome.
NK cells expressing orphan inhibitory KIR are indeed present in
most NK cell repertoires and pose a potential threat (Anfossi et al.,
2006). However, only NK cells expressing inhibitory receptors
for self-HLA class I acquire full functional competence, whereas
potential autoreactive NK cells remain in a hyporesponsive state,
a process referred to as education or licensing (Fernandez et al.,
2005; Kim et al., 2005, 2008; Anfossi et al., 2006; Yu et al., 2007;
Yawata et al., 2008).
In clinical stem cell transplantation, licensed NK cells become
potentially alloreactive when transferred in an HLA class I mis-
matched patient. Moreover, non-licensed NK cells might be
reactivated in the cytokine-rich environment of the reconstituting
hematopoietic system, providing an additional source of alloreac-
tive NK cells (Hsu et al., 2005, 2006; Clausen et al., 2007; Miller
et al., 2007). In this regard, it could be shown that NK cells can
be aberrantly activated after transplantation and achieve effector
function and functional competence in spite of lacking class I
ligand for donor inhibitory KIR (Hsu et al., 2005, 2006; Clausen
et al., 2007; Miller et al., 2007; Yu et al., 2009). Moreover, Yu et al.
(2009) revealed that in HSCT settings “unlicensed” NK cells with
inhibitory KIR for non-self-HLA are functional while “licensed”
NK cells with inhibitory KIR for self-HLA appeared to be hyperre-
sponsive. These ﬁndings were opposed by Bjorklund et al. (2010)
who demonstrated that NK cells without self-HLA receptors
remained hyporesponsive after HSCT thus remaining tolerant.
In contrast, Vago et al. (2008) showed a general hyporesponsive-
ness of NK cells in the presence of leukemic blasts. Licensed and
unlicensed NK cell subsets with alloreactive potential can be quali-
tatively predicted in theHSCTsetting as outlined inTable 1 and the
size of the alloreactive populations estimated by ﬂow cytometry.
Another interesting facet of KIR-mediated alloreactivity is given
by the recently described education of stimulatory KIR. It was
shown that NK cells expressing KIR2DS1, which is an activating
receptor speciﬁc for theHLA-C2 allotype are functional onlywhen
derived fromHLA-C1/C2 orHLA-C1/C1 donors but hyporespon-
sive in donors homozygous for HLA-C2. The data imply that
expression of KIR2DS1 in the presence of HLA-C2 generally ren-
ders NK cells hyporesponsive independent of inhibitory KIR or
Table 1 | Pattern of NK cell licensing and alloreactivity for
HLA-C-encoded KIR ligands.
Donor Education Recipient Alloreactive NK cells
KIR ligand Licensed Unlicensed KIR ligand Licensed Unlicensed
C1/C1 KIR2DL3 KIR2DL1 C1/C1 – KIR2DL1
C1/C2 KIR2DL1/
KIR2DL3
– C1/C1 KIR2DL1 –
C2/C2 KIR2DL1 KIR2DL3 C1/C1 KIR2DL1 –
C1/C1 KIR2DL3 KIR2DL1 C1/C2 – –
C1/C2 KIR2DL1/
KIR2DL3
– C1/C2 – –
C2/C2 KIR2DL1 KIR2DL3 C1/C2 – –
C1/C1 KIR2DL3 KIR2DL1 C2/C2 KIR2DL3 –
C1/C2 KIR2DL1/
KIR2DL3
– C2/C2 KIR2DL3 –
C2/C2 KIR2DL1 KIR2DL3 C2/C2 – KIR2DL3
Of note, to keep the scheme simple the contribution of KIR2DL2 and KIR2DS1
were not considered here.
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CD94/NKG2A expression (Fauriat et al., 2010). In line with this,
in a recent evaluation of allogeneic HSCT for AML, grafts possess-
ing KIR2DS1 on a C1/C1 background were associated with the
lowest incidence of relapse (Venstrom et al., 2012). However, no
signiﬁcant effect of KIR2DS1 was seen in C2/C2 patients, which
generally exhibitedworse outcome compared toC1/C1. It was thus
suggested that the lack of C2/C2 (or alternatively the presence of
C1/C1) is another dominant genetic inﬂuence in AML patients
that is independent of KIR2DS1 (Fischer et al., 2007; Fischer and
Uhrberg, 2012). Remarkably, Pende et al. (2009) reported that
KIR2DS1-expressing NK cell clones generated from C2/C2 recipi-
ents following haploidentical transplantationwere highly cytolytic
against patients’ C2/C2 leukemic blasts and overriding inhibition
by NKG2A or inhibitory KIR. Clearly, the clinical role of KIR2DS1
and other stimulatory KIR for NK cell alloreactivity should be
clariﬁed in further studies.
DEVELOPMENT OF ALLOGENEIC NK CELL REPERTOIRES
Natural killer cells develop from hematopoietic progenitor cells
(HPC) in distinct stages, deﬁned by a panel of surface markers
(Yokoyama et al., 2004; Freud et al., 2006; Caligiuri, 2008). NK
progenitor cells (CD34dim/CD117−/NKG2A−) differentiate into
immature CD56+ NK cells, which still lack the CD94/NKG2A
heterodimer (CD34−/CD117+/CD56+/−). In a next step, these
immatureNKcells develop intoCD56bright NKcells, which express
CD94/NKG2A (CD34−/CD117+/−/CD94+). Finally, mature NK
cells are characterized by CD56dim, CD16+ and either NKG2A or
KIR expression (CD34−/CD117−/CD94+/CD16+/KIR+; Freud
et al., 2006). In this context, it was already shown that CD56bright
cells found in peripheral blood and secondary lymphoid organs
can be directly differentiated into mature CD56dimCD16+ NK
cells (Ferlazzo et al.,2004; Chan et al.,2007; Romagnani et al.,2007;
Huntington et al., 2009).
After HSCT, NK cells are known to be the lymphocyte subset
showing the fastest reconstitution in vivo, which is a prerequisite
to efﬁciently exert antileukemic effects early after HSCT (Pfeif-
fer et al., 2010). They are CD56+ and predominantly CD16−
and KIR−. It could be shown that CD56dim NK cells from
patients who recently underwent hematopoietic transplantation
transiently overexpress NKG2A, compared with cells from healthy
donors (Dulphy et al., 2008; Vago et al., 2008; Beziat et al., 2009,
2010). In many respects, the early recovering NK cells closely
resemble the CD56bright subset of peripheral blood NK cells,
whereas the fraction of cells corresponding to the CD56dimCD16+
NK cell fraction increases and predominates at later times after
transplantation (Shilling et al., 2003). This orderly appearance
of CD56bright and CD56dimCD16+ subsets supports the model
that CD56bright cells are the principal progenitors of mature
CD56dimCD16+ NK cells.
Another factor that inﬂuences the composition of allogeneic
NK cell repertoires following HSCT is the sequential mode of
KIR acquisition during NK cell differentiation. In vitro, NK
cell differentiation from hematopoietic progenitors leads to early
expression of KIR2DL2/3 whereas KIR2DL1 is only expressed at
later time points (Miller and McCullar, 2001; Schonberg et al.,
2011b). The model of differentiation is given in Figure 1. Similar
observations were made in studies following the reconstitution of
NK cell repertoires following HSCT (Shilling et al., 2003). These
patterns of expression inﬂuence the overall frequency of func-
tionally competent NK cells including putative leukemia-reactive
clones. In this context, it could be shown that the presence of
HLA-C1, which is the ligand for the early-expressed KIR recep-
tor KIR2DL3 was associated with increased survival if present in
the recipient, whereas the presence of HLA-C2 ligands in the
recipient constituted a risk factor (Fischer et al., 2007). These
ﬁndings were in line with previous clinical observations (Giebel
et al., 2003; Hsu et al., 2005). Notably, HLA-C allele matching
(four-digit level) had differential effects in HLA-C1 (C1/C1) and
HLA-C2 (C1/C2 and C2/C2) subgroups of patients: in HLA-C1
patients with myeloid leukemia, HLA-C-matching was associ-
ated with improved survival as described previously (Morishima
et al., 2002; Flomenberg et al., 2004; Petersdorf et al., 2004; Wool-
frey et al., 2011). Surprisingly, the opposite was true for HLA-C2
patients, which proﬁted from having an HLA-C allele mismatch
on the allelic level (Fischer et al., 2012), i.e., two different HLA-
C-alleles that both belong to the HLA-C2 ligand group. HLA-C2
patients with these allele-mismatched, but “KIR-neutral” donors
generally showed superior survival with substantial improvement
in treatment related mortality and relapse incidence compared
to HLA-C1 patients with HLA-C mismatches. The data sug-
gest that HLA-C mismatching should be avoided in HLA-C1
patients as reported previously but might be favorable for HLA-
C2 patients. Furthermore, the study suggested a novel model
in which matched HLA-C1 and mismatched HLA-C2 patients
constitute a low-risk group, whereas mismatched HLA-C1 and
matched HLA-C2 patients would represent a high-risk group with
inferior overall survival, increased TRMand higher relapse rate [in
myeloid leukemia and myelodysplasia syndrome (MDS); Fischer
et al., 2012].
KIR GENETICS AND ALLOREACTIVITY
Two KIR haplotype groups, A and B, have been identiﬁed based
on differential KIR gene content (Uhrberg et al., 1997). Group A
and B haplotypes have four framework genes in common: the KIR
gene cluster is ﬂanked by the non-expressed KIR3DL3 at the cen-
tromeric end, KIR3DL2 at the telomeric end, with KIR3DP1 and
KIR2DL4 in themiddle. Deletion andduplication of genes have led
to many different haplotypes (Vierra-Green et al., 2012). Group A
haplotypes are present in all populations and consist of ﬁve pro-
ductive inhibitory KIR (KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1,
KIR3DL2), and the stimulatory KIR2DS4, which is frequently
present in an allelic variant that is not expressed on the cell surface
(Maxwell et al., 2002). Group B comprises KIR haplotypes with
diverse gene content including several genes (KIR2DL2, KIR2DL5,
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1) that are
not part of group A haplotypes. As a consequence, most group
B haplotypes encode more activating KIRs compared to group A
haplotypes. All individuals can be categorized as having one of
two KIR genotypes: A/A, which is homozygous for group A KIR
haplotypes, or B/x, which contains either one (A/B heterozygotes)
or two (B/B homozygotes) group B haplotypes.
There have only been a few studies regarding the impact
of genetic polymorphisms of activating and inhibitory KIR
in humans on the susceptibility and resistance to leukemia.
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FIGURE 1 | Model of NK cell reconstitution and NK cell receptor
expression following allogeneic HSCT.The HLA-C1-speciﬁc
KIR2DL2/3 receptor is expressed at earlier time points on reconstituting
NK cells than the HLA-C2-speciﬁc KIR2DL1 (Shilling et al., 2003; Nguyen
et al., 2005; Fischer et al., 2007). Thus, in the clinical setting C2/C2
recipients possess a lower frequency of functionally competent NK cells
(expressing KIR2DL1) than C1/C1 patients (expressing KIR2DL2/3),
which may lead to a disadvantage in the early phase following
HSCT. The model is compatible with decreased overall survival
rates and increased relapse rates in C2/C2 individuals that
were found in several different studies (Fischer et al., 2007, 2012;
Venstrom et al., 2012).
Verheyden et al. (2004) revealed an association of the inhibitory
KIR2DL2 gene with leukemia. In a polymorphic cohort of AML,
ALL, CML (chronic myeloid leukemia), and CLL (chronic lym-
phoblastic leukemia) patients they found a signiﬁcantly increased
frequency of the KIR haplotype combination A/B in leukemic
patients compared to controls. This ﬁnding was related to the
high prevalence of the inhibitory KIR2DL2 gene. Another signif-
icant association with leukemia was found for two distinct KIR
genotypes, which included all inhibitory KIRs (Uhrberg et al.,
2002; Verheyden and Demanet, 2008). In a more recent study
of pediatric ALL patients, Almalte et al. (2011) reported a highly
signiﬁcant association between the presence of stimulatory KIR
genes and decreased risk for ALL. The risk for ALL progressively
decreased with the cumulative number of stimulatory KIR. In a
subsequent study, no signiﬁcant association was found between
childhood ALL and stimulatory KIR genes (Babor et al., 2012). In
the latter study neither stimulatory nor inhibitory genes exhibited
a signiﬁcant deviation in frequency from an ethnically matched
control group. Analyses of the cumulative number of stimulatory
and inhibitory KIR genes as well as further analysis of telomeric
and centromeric KIR haplotypes did not reveal any signiﬁcant dif-
ference to the control cohort. Similarly, in a recent study analyzing
a large cohort of AML patients, frequencies of stimulatory KIR
genes were again not different to published healthy donor cohorts
(Venstrom et al., 2012). More thorough analysis of KIR genes on
the allelic level will be necessary to settle the question if KIR genes
constitute amajor disease susceptibility locus for acute leukemia in
children and adults. Notably, the identiﬁcation of single KIR genes
as disease markers is generally complicated by the fact that groups
of KIR genes are tightly linked in a small number of common cen-
tromeric and telomeric haplotypes (Uhrberg, 2005a). Moreover,
centromeric KIR genes could be linked to the neighboring LIR
gene family including inhibitory and stimulatory LIR genes that
are known to be expressed onNK cells as well (Cosman et al., 1997;
Young et al., 2001).
In the clinical transplant setting, Stringaris et al. (2010) revealed
that three donor B haplotype KIR genes, KIR2DL5A, KIR2DS1,
and KIR3DS1, were associated with signiﬁcantly less relapse in
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patients with AML undergoing HLA-identical sibling HSCT. The
authors could not conﬁrm these ﬁndings in patients with other
myeloid or lymphoid malignancies. Recent data suggest evidence
of beneﬁcial effects of KIR B genotype donors in AML patients
in an unrelated HLA-matched HSCT setting (Cooley et al., 2009,
2010). Cooley et al. (2009) analyzed the effect of KIR genotypes
on outcome in a comparatively homogeneous study cohort of 448
AML patients who received T cell replete transplants from unre-
lated donors. They could show that the use of donors with KIR
group B haplotypes was associated with signiﬁcant improvement
in relapse-free and overall survival, with 30% better relative risk
in both endpoints. The same group subsequently performed anal-
yses regarding gene content motifs, which further revealed that
comparedwith groupA haplotypemotifs, centromeric and telom-
eric group B motifs both contributed to relapse protection and
improved survival. Centromeric B homozygosity (Cen-B/B) had
the strongest independent effect. Overall, signiﬁcantly reduced
relapse was achieved with donors having two or more B gene-
contentmotifs in bothHLA-matched andmismatched transplants
(Cooley et al., 2010). In contrast, Venstrom et al. (2012) revealed
in their study of AML transplant patients a beneﬁcial effect
of telomeric but not centromeric genes, namely KIR2DS1 and
KIR3DS1. Together, these ﬁndings highlight the need for further
studies of KIR polymorphism in HSCT, possibly on the allelic
level, to enable incorporation of KIR gene content status along
with HLA-matching in future algorithms for donor selection in
allogeneic/haploidentical HSCT settings.
EXPLOITING KIR AND KIR LIGAND MISMATCHING IN HSCT
In HSCT settings, donor-derived T cells are essential not only
for early cellular engraftment following HSCT but also for erad-
ication of remaining leukemic blasts. On the other hand, T cells
are major effectors of rejection or acute or chronic graft versus
host disease (GvHD). T cell-mediated alloreactivity is directed
against histocompatibility antigens not only displayed on the stem
cell recipient’s leukemic cells but also on other tissues. Espe-
cially cytotoxic CD8+ effector T cells may then attack tissues such
as liver, intestines, and skin, which results in acute or chronic
GvHD. Currently, in order to avoid GvHD various manipulations
of HSCT grafts such as CD6+ T cell depletion (Soiffer et al., 2001),
CD3+/CD19+ T and B cell depletion (Federmann et al., 2012) or
α/β T cell (Handgretinger, 2012) depletion are implemented in
different transplant centers. With this approach, the numbers of
potentially graft rejecting or GvHD causing T cells can be reduced
considerably while HPC and NK cells remain in the graft and
can be transferred into the patient. Such grafts, mainly consisting
of mature NK cells, CD34+ stem cells and only a few remaining
T cells (max. 5 × 104/kg BW) of donor origin repopulate the
recipient’s hematopoietic system and rebuild the recipient’s new
immune system that quickly reconstitutes immunity to viral and
bacterial infections and eliminates leukemic blasts that survived
chemotherapy (graft versus leukemia effect – GvL). Especially in
CD3+/CD19+ depleted grafts large numbers of mature donor NK
cells are co-transfused.
Previous in vitro studies already demonstrated the alloreactive
potential of NKcells (Ciccone et al., 1992; Colonna et al., 1992) and
showed that the kind and frequency of alloreactive NK cells can be
predicted if KIR expression in the donor and presence of KIR lig-
ands in the recipient are known (Valiante et al., 1997). The clinical
contribution of NK cells to alloreactivity was impressively shown
by Ruggeri et al. (2002) who demonstrated a strong GvL effect
for AML patients receiving a haploidentical allogeneic transplant
mismatched for HLA-C KIR ligands. In this setting alloreactive
donor-derived NK cells are thought to promote engraftment,
reduce GVHD, and decrease leukemic relapse. Whereas some
subsequent studies did conﬁrm the KIR ligand mismatch model
(Giebel et al., 2003) others could not ﬁnd a beneﬁcial effect of KIR
ligand mismatching (Davies et al., 2002; Hsu et al., 2006; Miller
et al., 2007), which might be explained by speciﬁc differences in
HSCT protocols performed in the different transplant centers.
Subsequently, several modiﬁed donor selection models were sug-
gested based on the consideration that donor NK cells expressing
a certain inhibitory KIR would be alloreactive if the respective lig-
ands (C1, C2, or Bw4) in the patient are missing. This model was
originally proposedby Leung et al. (2004) anddemonstratedbetter
clinical outcome in haploidentical HSCT for pediatric lymphoid
leukemia thereby prooﬁng that NK cell-mediated relapse control
is not restricted to myeloid leukemia. Hsu et al. (2005) applied the
same model to HLA-identical HSCT showing that patients with
missing KIR ligands for which the donor possessed a speciﬁc KIR
exhibited increased survival through decreased relapse incidence
in AML and MDS patients. An overview of studies investigating
the role of KIR genes in clinical stem cell transplantation is given
in Table 2.
NK CELL IMMUNOTHERAPY: ONLY AT THE BEGINNING OF
GREAT POSSIBILITIES?
Cytokines such as IL-2, IL-15, and IL-21, as well as the combi-
nation of IL-12 and IL-18 are known to activate NK cells (Carson
et al., 1995; Singh et al., 2000; Trinchieri, 2003; Young and Ortaldo,
2006). Coadministration of suchNKcell-activating cytokines have
the potential to increase survival of adoptively transferred NK
cells, enhance proliferation, up-regulation of cytotoxic and adhe-
sion molecules, augment cytokine production and increase GvL
effects (Becknell and Caligiuri, 2005). IL-2 activated NK cells kill
tumor cells in vitro and in vivo by localizing to the tumor sites
to elicit their cytotoxic action and they prolong the survival of
tumor bearing mice. This was seen in mice with multiple myeloma
(Alici et al., 2007) and in NOD/SCID mice with metastatic neu-
roblastoma (Castriconi et al., 2004). Unfortunately, administered
cytokines such as IL-2, IL-15, or IL-18 are rapidly cleared, thus
requiring repeated injections (subcutaneous) of large amounts.
This in turn increases the potential for toxicity considerably and
furthermore might elicit activation of unwanted cell populations
or even cause activation-induced cell death of NK cells. IL-2 but
not IL-15 is known to be involved in the maintenance of T regula-
tory cells (Treg), which could impair antitumor immune response
(Waldmann, 2006). Thus, IL-15 administration holds promise to
speciﬁcally boost NK cell alloreactivity without undesired stimu-
lation of Tregs. Importantly, the use of IL-15 as GMP product has
recently been approved by the U.S. Food and DrugAdministration
(FDA).However, since full biological activity of IL-15 is dependent
on its trans-presentation on the cell surface, suitable application
strategies have to be developed to increase biological stability and
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Table 2 | An overview of studies analyzing the role of KIR for susceptibility and clinical HSCT for leukemia.
KIR/model Observation Disease Treatment Reference
Genetic associations KIR2DL2 Increased frequency AML/ALL – (Verheyden et al., 2004)
KIR-S Decreased frequency ped. ALL – (Almalte et al., 2011)
KIR-L / KIR-S No association ped ALL – (Babor et al., 2012)
Inhibitory KIR Missing KIR ligand Relapse ↓ ped. AML/ALL Haploidentical (Leung et al., 2004)
Missing KIR Ligand Survival ↑, Relapse ↓ AML/ALL MSD HSCT (Hsu et al., 2005)
KIR ligand mismatch Relapse ↓, Survival ↑ AML Haploidentical (Ruggeri et al., 2007)
KIR3DL1 Survival ↓ Acute leukemia Unrelated HSCT (Gagne et al., 2009)
Stimulatory KIR KIR2DS2 Survival ↓ AML (ALL) MSD HSCT (Cook et al., 2004)
KIR3DS1 Survival ↓ Acute leukemia Unrelated HSCT (Gagne et al., 2009)
KIR2DS1 Relapse ↓ AML Unrelated HSCT (Venstrom et al., 2012)
Haplotype structure Group B Relapse ↓ chronic GvHD ↑ Adult AML Unrelated HSCT (Cooley et al., 2009)
Group B haplotype score Relapse ↓ AML (ALL) Unrelated HSCT (Cooley et al., 2010)
HSCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; Cen, centromeric; MSD, matched sibling donor;
ped, pediatric; indiv, individuals.
activity. These include administration of pre-associated complexes
of IL-15 with soluble IL-15Rα-IgG1-Fc or stimulation of native
IL-15Rα expression with, e.g., anti-CD40 (Zhang et al., 2009; Steel
et al., 2012).
Advanced cell therapy trials with donor NK cells post-
haploidentical stem cell transplantation provide a promising
treatment option for patients with high risk leukemia and tumors
(Leung et al., 2004, 2005). While the established adoptive T cell
therapies are associated with the risk of GvHD, NK cells mediate
GvL effects without substantial induction of acute GvHD. These
ﬁndings encouraged scientists and clinicians to conduct clinical
trials utilizing adoptive transfer of cytokine-activated NK cells,
which could serve as an attractive cell therapy option not only
in recipients of haploidentical stem cell transplantation but in
other oncologic diseases as well (Miller et al., 2005; Passweg et al.,
2006; Rubnitz et al., 2010). In 2005, Miller and colleagues were
the ﬁrst to infuse haploidentical NK cells into AML recipients in
a non-transplant setting (Miller et al., 2005). Before NK cell infu-
sion patients received an intensive immunosuppressive regimen of
low-dose cyclophosphamide and methylprednisolone or ﬂudara-
bine. Successful transfer of haploidentical KIR ligand-mismatched
NK cells was followed by a subcutaneous administration of IL-2
for 2 weeks. NK cells expanded in vivo and were functional at day
14 following infusion (Miller et al., 2005). But still, the intensive
conditioning regimen and high doses of IL-2 resulted in signiﬁcant
hematologic and non-hematologic toxicities as well as prolonged
hospitalization. In order to further optimize this strategy of
donor-derived NK cell transfer, Rubnitz et al. (2010) extended
investigations concerning the safety and feasibility of low-dose
immunosuppression followed by NK cell infusion. This study on
transfer of alloreactive haploidentical KIR ligand-mismatched NK
cells has been performed in children with AML after achievement
of complete remission. In order to minimize toxicity while still
allowing engraftment of haploidentical NK cells a low-intensity
regimen was administered to patients followed by NK cell infusion
andmultiple doses of IL-2. The study gave encouraging results, and
has allowed commencement of a phase II trial as consolidation
therapy in children with AML. In multiple myeloma, infusion of
haploidentical KIR ligand-mismatched NK cells after condition-
ing therapy with melphalan and ﬂudarabine has been proposed in
relapsedpatients (Shi et al., 2008). Curti et al. (2011) demonstrated
that infusion of puriﬁed NK cells is feasible and safe in elderly
patients with high-risk AML and these donor alloreactive NK cells
were shown to kill recipient leukemia cells. Again, no NK cell-
related toxicity, including GVHD, was observed. Donor-versus-
recipient alloreactive NK cells were shown in vivo by the detection
of donor-derived NK clones that killed recipient’s targets.
Together, these trials show that adoptive immunotherapy with
haploidentical NK cells obtained from KIR ligand-mismatched
donors is feasible and safe in adults as well as in children. Never-
theless, further studies are highly warranted to speciﬁcally assess
the role of NK cell therapy to elucidate which patient collective
(AML/ALL/adults/children) is best suited at which stage of dis-
ease (remission/relapse) and at which stage of therapy (after/prior
to/without HSCT). Furthermore, these studies should address the
question, which NK cell subset (single KIR+ NK cells, licensed or
unlicensed) mediates strongest reactivity against leukemia.
CONCLUSION
KIR genes have two unusual features that could be harnessed for
improving current HSCT strategies: ﬁrstly, KIR genes are highly
polymorphic leading to novel opportunities beyond classical HLA
matching strategies for selection of optimal stem cell donors based
on KIR genetic diversity. Secondly, KIR are expressed in a clonally
distributed manner, which leads to the formation of NK cell reper-
toires encompassing tolerant as well as potentially alloreactive NK
cell clones. Both features have a great potential to be exploited in
the setting of clinical stem cell transplantation.
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While recent studies could not detect a predisposition for
leukemia based on presence or absence of particular inhibitory
and stimulatory KIR genes or KIR haplotype classiﬁcation, there
is growing evidence for beneﬁcial effects of KIRB genotype donors
in HSCT for AML. In general, NK cells and their variable capa-
bility of killing residual leukemic blasts become a criterion of
growing importance as clinicians are offered another important
factor concerning donor selection in unrelated, sibling, and hap-
loidentical transplant settings along with HLA matching, CMV
status, blood group, age, and gender. Furthermore, recent inves-
tigations suggest that homozygous HLA-C2 stem cell transplant
recipients constitute a high-risk group that needs special attention.
In this regard, recent data suggest that survival of C2/C2 patients
might be improved by allele mismatching of donor/recipient pairs
for HLA-C2, a novel concept that has to be conﬁrmed in ret-
rospective studies of larger cohorts. On the basis of optimally
deﬁned matching/mismatching strategies an important next step
for successful NK cell-based intervention in HSCT will be to
qualitatively and quantitatively deﬁne patient-speciﬁc alloreactive
subsets among donor NK cell repertoires opening the possibility
to stimulate, enrich, and expand those subsets in vitro or in vivo
for immunotherapy.
Antileukemic NK cells, either allogeneic or unlicensed autol-
ogous NK cells, emerge as a feasible therapy option and might
improve clinical outcome in myloid leukemia. Further integration
into established HSCT protocols may indeed improve survival
rates in adults and children. It will be an important task to
deﬁne, which patients are most suitable for NK cell-mediated
antileukemic therapy based on incorporation of multiple factors
like genetic predisposition, HLA, KIR and the nature of leukemic
disease. It would be desirable to expand the possible range of
applications to ALL and lymphoma as well as toward NK cell-
based therapy of solid tumors. Toward this goal, our biological
understanding of NK cell function and interaction with leukemic
target cells has to be further improved.
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